Atacicept

Research use only, not for human use.

Atacicept (TACI-Ig) is a homodimeric fusion protein that inhibits B-cell stimulation by binding to B-lymphocyte stimulatory factors and proliferation-inducing ligands, and can be used in the study of systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, and various B-cell malignancies.

Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease.

——

Atacicept (TACI-Ig; 100 μg; i.p.; three times of week for 14 days; BALB/c mice) reduces mature B-cell counts and serum antibody levels in normal mice.Atacicept (TACI-Ig) inhibits the progression of disease and autoantibody titers in a mouse model of collagen-induced arthritis (CIA).Animal Model:Male DBA/1 mice with CIA modelsDosage:100 μg Administration:intraperitoneal injection; three times of week for 21 days Result:Increased serum titers of anti-collagen Abs and few overt signs of disease.Animal Model:BALB/c mice Dosage:100 μg Administration:intraperitoneal injection; three times of week for 14 days Result:Reduced mature B cell populations but had little effect on other cell lineages.Blocked the development of B cells at the transition from T1 to T2 and the development of MZ B cells in the spleen.

——

Others

Other Targets

Others

——

——

845264-92-8

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years